预给药可增强177Lu-奥曲肽对携带人小肠神经内分泌肿瘤GOT1的裸鼠的抗肿瘤效果并拓宽治疗窗
该研究在移植人小肠神经内分泌肿瘤GOT1的裸鼠中比较177Lu-奥曲肽预给药后24小时二次注射与单次给药的抗肿瘤效果。预给药使每单位给药活度的肿瘤平均吸收剂量提高1.9倍,同时降低肾脏平均吸收剂量,并取得最佳总体抗肿瘤效果。磁共振成像显示有无预给药两组肿瘤反应无统计学显著差异。作者认为预给药是177Lu-奥曲肽治疗神经内分泌肿瘤的一种有意义的优化策略,需进一步研究确定相关机制。
要点
- 预给药使每单位给药活度的肿瘤平均吸收剂量提高1.9倍,同时降低肾脏平均吸收剂量。
- 预给药取得最佳总体抗肿瘤效果,并拓宽治疗窗。
- 磁共振成像显示有无预给药两组肿瘤反应无统计学显著差异。
核心结论
- 预给药取得最佳总体抗肿瘤效果,并拓宽治疗窗。
- 结果提示肿瘤再生长的潜在生物标志物可能存在于p53或JNK信号通路中。
- 作者认为预给药是177Lu-奥曲肽治疗神经内分泌肿瘤的一种有意义的优化策略,需进一步研究确定所报告效应的机制。
研究设计与样本
- 研究在移植人小肠神经内分泌肿瘤细胞系GOT1的裸鼠中进行,比较177Lu-奥曲肽预给药后24小时二次注射与单次给药的抗肿瘤效果。
主要发现
- 预给药使每单位给药活度的肿瘤平均吸收剂量提高1.9倍,同时降低肾脏平均吸收剂量。
- 预给药取得最佳总体抗肿瘤效果。
- 磁共振成像显示有无预给药两组肿瘤反应无统计学显著差异。
- 基因表达分析显示对细胞周期调控的影响;在生物分布与剂量学研究中,与凋亡性细胞死亡相关的生物学过程受到高度影响,涉及APOE、BAX、CDKN1A和GADD45A等的差异调控。
局限性
- 作者指出需进一步研究确定所报告效应的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 177Lu-[DOTA0, Tyr3]-octreotate (177Lu-octreotate) is used for treatment of patients with somatostatin receptor (SSTR) expressing neuroendocrine tumors. However, complete tumor remission is rarely seen, and optimization of treatment protocols is needed. In vitro studies have shown that irradiation can up-regulate the expression of SSTR1, 2 and 5, and increase 177Lu-octreotate uptake. The aim of the present study was to examine the anti-tumor effect of a 177Lu-octreotate priming dose followed 24 h later by a second injection of 177Lu-octreotate compared to a single administration of 177Lu-octreotate, performed on the human small intestine neuroendocrine tumor cell line, GOT1, transplanted to nude mice. RESULTS: Priming resulted in a 1.9 times higher mean absorbed dose to the tumor tissue per administered activity, together with a reduced mean absorbed dose for kidneys. Priming gave the best overall anti-tumor effects. Magnetic resonance imaging showed no statistically significant difference in tumor response between treatment with and without priming. Gene expression analysis demonstrated effects on cell cycle regulation. Biological processes associated with apoptotic cell death were highly affected in the biodistribution and dosimetry study, via differential regulation of, e.g., APOE, BAX, CDKN1A, and GADD45A. CONCLUSIONS: Priming had the best overall anti-tumor effects and also resulted in an increased therapeutic window. Results indicate that potential biomarkers for tumor regrowth may be found in the p53 or JNK signaling pathways. Priming administration is an interesting optimization strategy for 177Lu-octreotate therapy of neuroendocrine tumors, and further studies should be performed to determine the mechanisms responsible for the reported effects.
引用
- Dalmo J, Spetz J, Montelius M, et al. Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1. EJNMMI Res. 2017. PMID: 28097640. doi:10.1186/s13550-016-0247-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。